2023, Volume 26, Issue 7
Engineering >> 2023, Volume 26, Issue 7 doi: 10.1016/j.eng.2022.09.012
Novel Insight into the Etiology of Haff Disease by Mapping the N-Glycome with Orthogonal Mass Spectrometry
a The Key Laboratory for Biomedical Photonics of the MOE at Wuhan National Laboratory for Optoelectronics–Hubei Bioinformatics and Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
b Wuhan Center for Disease Control & Prevention, Wuhan 430015, China
Next Previous
Abstract
Consumption of boiled crayfish may lead to Haff disease (HD), which is considered to result from an unidentified toxin, although the etiology is still obscure. Profiling of the N-glycome in HD would assist in deciphering the underlying molecular mechanism of the disease, whereas HD-associated glycosylation has never been explored. Herein, we enrolled 90 serum samples with HD patients and healthy controls from the Wuhan Center for Disease Control & Prevention between 2019 and 2020. N-glycome profiles of both serum and serum-derived immunoglobulin G (IgG) in HD were characterized by means of high-throughput-based orthogonal mass spectrometry. It was observed that HD is associated with an increase in the core fucosylation and mono-galactosylation of total serum glycoproteins. The serum level of IgG was found to serve as a good indicator for HD patients. In addition, differential galactosylation and sialylation of IgG were strongly correlated with HD. It was notable that the changes in the galactosylation and sialylation of IgG1 and IgG2 were subclass specific. Interestingly, altered sialylation and galactosylation of IgG2 or IgG3/4 strongly correlated with clinical markers for HD. Our study reveals the association of differential IgG N-glycosylation with HD, providing new insight into the etiology of this rare disease.
Keywords
Haff disease ; Serum ; Immunoglobulin G ; Glycosylation ; Disease pathogenesis
SupplementaryMaterials
Figures
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
References
[ 1 ] Diaz JH. Global incidence of rhabdomyolysis after cooked seafood consumption (Haff disease). Clin Toxicol 2015;53(5):421–6. link1
[ 2 ] Buchholz U, Mouzin E, Dickey R, Moolenaar R, Sass N, Mascola L. Haff disease: from the Baltic Sea to the US shore. Emerg Infect Dis 2000;6(2):192–5. link1
[ 3 ] Taniyama S, Sagara T, Nishio S, Kuroki R, Asakawa M, Noguchi T, et al. Survey of food poisoning incidents in Japan due to ingestion of marine boxfish and their toxicity. Shokuhin Eiseigaku Zasshi 2009;50(5):270–7. Japanese. link1
[ 4 ] Huang X, Li Y, Huang Q, Liang J, Liang C, Chen B, et al. A past Haff disease outbreak associated with eating freshwater pomfret in south China. BMC Public Health 2013;13(1):447. link1
[ 5 ] Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Intern Med 2007;18(2):90–100. link1
[ 6 ] Chan TY. The emergence and epidemiology of Haff disease in China. Toxins 2016;8(12):359. link1
[ 7 ] Dang K, Jiang S, Gao Y, Qian A. The role of protein glycosylation in muscle diseases. Mol Biol Rep 2022;49(8):8037–49. link1
[ 8 ] Paton B, Suarez M, Herrero P, Canela N. Glycosylation biomarkers associated with age-related diseases and current methods for glycan analysis. Int J Mol Sci 2021;22(11):5788. link1
[ 9 ] Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol 2019;15(6):346–66. link1
[10] Reiding KR, Ruhaak LR, Uh HW, El Bouhaddani S, van den Akker EB, Plomp R, et al. Human plasma N-glycosylation as analyzed by matrix-assisted laser desorption/ionization-fourier transform ion cyclotron resonance-MS associates with markers of inflammation and metabolic health. Mol Cell Proteomics 2017;16(2):228–42. link1
[11] Zhang Y, Jiao J, Yang P, Lu H. Mass spectrometry-based N-glycoproteomics for cancer biomarker discovery. Clin Proteomics 2014;11(1):18. link1
[12] Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta 2012;1820(9):1347–53. link1
[13] Hart GW, Wells L. Glycoproteomics: making the study of the most structurally diverse and most abundant post-translational modifications more accessible to the scientific community. Mol Cell Proteomics 2021;20:100086. link1
[14] Gao X, Song X, Zuo R, Yang D, Ji C, Ji H, et al. Ionophore toxin maduramicin produces haff disease-like rhabdomyolysis in a mouse model. Int J Environ Res Public Health 2020;17(21):7882. link1
[15] Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17(7):1055–65. link1
[16] Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012;1253(1):170–80. link1
[17] Cobb BA. The history of IgG glycosylation and where we are now. Glycobiology 2020;30(4):202–13. link1
[18] Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell 2018;9(1):63–73. link1
[19] Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014;5:520. link1
[20] Van Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, MauserBunschoten EP, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008;142 (4):644–52. link1
[21] Liu S, Cheng L, Fu Y, Liu BF, Liu X. Characterization of IgG N-glycome profile in colorectal cancer progression by MALDI-TOF-MS. J Proteomics 2018;181:225–37. link1
[22] Liu X, Qiu H, Lee RK, Chen W, Li J. Methylamidation for sialoglycomics by MALDI-MS: a facile derivatization strategy for both a2,3- and a2,6-linked sialic acids. Anal Chem 2010;82(19):8300–6. link1
[23] Zhang Q, Feng X, Li H, Liu BF, Lin Y, Liu X. Methylamidation for isomeric profiling of sialylated glycans by nanoLC-MS. Anal Chem 2014;86 (15):7913–9. link1
[24] Liu S, Fu Y, Huang Z, Liu Y, Liu BF, Cheng L, et al. A comprehensive analysis of subclass-specific IgG glycosylation in colorectal cancer progression by nanoLCMS/MS. Analyst 2020;145(8):3136–47. link1
[25] Kang P, Mechref Y, Novotny MV. High-throughput solid-phase permethylation of glycans prior to mass spectrometry. Rapid Commun Mass Spectrom 2008;22(5):721–34. link1
[26] Zhang Z, Westhrin M, Bondt A, Wuhrer M, Standal T, Holst S. Serum protein Nglycosylation changes in multiple myeloma. Biochim Biophys Acta, Gen Subj 2019;1863(5):960–70. link1
[27] Liu Y, Wang C, Wang R, Wu Y, Zhang L, Liu BF, et al. Isomer-specific profiling of N-glycans derived from human serum for potential biomarker discovery in pancreatic cancer. J Proteomics 2018;181:160–9. link1
[28] Kao D, Danzer H, Collin M, Groß A, Eichler J, Stambuk J, et al. A monosaccharide residue is sufficient to maintain mouse and human IgG subclass activity and directs IgG effector functions to cellular Fc receptors. Cell Rep 2015;13 (11):2376–85. link1
[29] Liu S, Yu Y, Liu Y, Lin J, Fu Y, Cheng L, et al. Revealing the changes of IgG subclass-specific N-glycosylation in colorectal cancer progression by highthroughput assay. Proteomics Clin Appl 2021;15(2–3):e2000022. link1
[30] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57 (1):289–300. link1
[31] Bladergroen MR, Reiding KR, Hipgrave Ederveen AL, Vreeker GC, Clerc F, Holst S, et al. Automation of high-throughput mass spectrometry-based plasma Nglycome analysis with linkage-specific sialic acid esterification. J Proteome Res 2015;14(9):4080–6. link1
[32] Liu S, Liu X. IgG N-glycans. Adv Clin Chem 2021;105:1–47. link1
[33] Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 2015;15(9):540–55. link1
[34] Pei P, Li XY, Lu SS, Liu Z, Wang R, Lu XC, et al. The emergence, epidemiology, and etiology of haff disease. Biomed Environ Sci 2019;32 (10):769–78. link1
[35] Stanley M, Chippa V, Aeddula NR, Quintanilla Rodriguez BS, Rhabdomyolysis AR. StatPearls. Treasure Island: StatPearls Publishing; 2022. link1
[36] Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon 2020;66(8):101015. link1
[37] Ahmad SC, Sim C, Sinert R. Elevated liver enzymes as a manifestation of haff disease. J Emerg Med 2019;57(6):e181–3. link1
[38] Florsheim EB, Sullivan ZA, Khoury-Hanold W, Medzhitov R. Food allergy as a biological food quality control system. Cell 2021;184(6):1440–54. link1
[39] Kostrzewa-Nowak D, Kubaszewska J, Nowakowska A, Nowak R. Effect of aerobic and anaerobic exercise on the complement system of proteins in healthy young males. J Clin Med 2020;9(8):2357. link1
[40] Dumic´ J, Cvetko A, Abramovic´ I, Šupraha Goreta S, Perovic´ A, Njire Braticˇevic´ M, et al. Changes in specific biomarkers indicate cardiac adaptive and antiinflammatory response of repeated recreational SCUBA diving. Front Cardiovasc Med 2022;9:855682. link1
[41] Nimmerjahn F, Ravetch JV. Four keys to unlock IgG. J Exp Med 2021;218(3): E20201753. link1
[42] Ohmi Y, Ise W, Harazono A, Takakura D, Fukuyama H, Baba Y, et al. Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. Nat Commun 2016;7(1):11205. link1
[43] Liu J, Liu S, Huang Z, Fu Y, Fei J, Liu X, et al. Associations between the serum levels of PFOS/PFOA and IgG N-glycosylation in adult or children. Environ Pollut 2020;265(Pt A):114285. link1
[44] Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 2012;12:13. link1
[45] Gornik O, Pavic´ T, Lauc G. Alternative glycosylation modulates function of IgG and other proteins—implications on evolution and disease. Biochim Biophys Acta 2012;1820(9):1318–26. link1
[46] Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci USA 2013;110(24):9868–72. link1
[47] Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13 (3):176–89. link1
[48] Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci USA 2017;114 (13):3485–90. link1
[49] Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol 2018;333:65–79. link1
[50] Nishima W, Miyashita N, Yamaguchi Y, Sugita Y, Re S. Effect of bisecting GlcNAc and core fucosylation on conformational properties of biantennary complex-type N-glycans in solution. J Phys Chem B 2012;116(29):8504–12. link1
[51] Jennewein MF, Alter G. The immunoregulatory roles of antibody glycosylation. Trends Immunol 2017;38(5):358–72. link1
[52] Verhelst X, Dias AM, Colombel JF, Vermeire S, Van Vlierberghe H, Callewaert N, et al. Protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases. Gastroenterology 2020;158 (1):95–110. link1
京公网安备 11010502051620号
